Subscribe to Pfizer

The Lead

Baxter to Sell Commercial Vaccines Business to Pfizer

July 30, 2014 8:06 am | News | Comments

Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.   

European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism

July 29, 2014 8:38 am | News | Comments

Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for...

Pfizer's Second Quarter Profit Sinks 79% But Tops Forecasts

July 29, 2014 8:30 am | News | Comments

Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-...

Obama Wants Limits on US Company Mergers Abroad

July 25, 2014 8:32 am | News | Comments

Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday...

View Sample

FREE Email Newsletter

Pfizer Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO)

July 16, 2014 11:15 am | News | Comments

Life expectancy continues to climb — up to more than 81 years for women and 76 years for men – but many of us have concerns around aging. Pfizer is challenging Americans to address their #FOGO – Fear of Getting Old – as the next phase of Get Old, an initiative by Pfizer around aging, encouraging honest conversations and celebrating getting “old” at whatever stage of life you are.

Pfizer to Acquire InnoPharma

July 16, 2014 9:34 am | News | Comments

Pfizer and InnoPharma, a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

Pfizer & Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration

June 18, 2014 9:19 am | by Pfizer | News | Comments

 Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.                           


Pfizer Submits BLA For Investigational Meningococcal Vaccine

June 17, 2014 9:17 am | by Pfizer | News | Comments

Pfizer Inc. announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

Pfizer Official Receives Diamond Award For Pharmaceutical Manufacturing

June 16, 2014 9:55 am | News | Comments

Patricia A. English is recognized by Continental Who's Who as 2014 Diamond Professional of the Year in the field of Pharmaceutical Manufacturing as a result of her role as Director of Oncology Statistics with Pfizer.               

New Pfizer Discount Keeps Brand-Name Lipitor Cheap

June 2, 2014 6:51 am | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Patients who prefer brand-name cholesterol drug Lipitor to an inexpensive generic version will find it more affordable, thanks to a new discount offer from drugmaker Pfizer Inc. They'll be able to get Lipitor, the highest-selling prescription medicine in history, for $30 or less per month— not much more than a generic.

Pfizer Names Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

May 29, 2014 11:33 am | News | Comments

Pfizer announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, MA.

Pfizer Launches OTC Nexium® 24HR

May 27, 2014 8:49 am | News | Comments

Pfizer today announced the introduction in the U.S. of over-the-counter (OTC) Nexium® 24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older).     


Pfizer Pulls Plug on Push to Buy AstraZeneca

May 26, 2014 11:30 am | by Alex Veiga - AP Business Writer - Associated Press | News | Comments

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history. The announcement came a week after AstraZeneca's board rejected a $119 billion buyout proposal from Pfizer.

BioRestorative Therapies Signs Research Agreement with Pfizer

May 22, 2014 8:28 am | News | Comments

BioRestorative Therapies has entered into a two-year collaborative research agreement with Pfizer to study human brown adipose tissue and cell lines.                 

Acura Pharmaceuticals Settles Patent Litigation With Sandoz

May 22, 2014 8:17 am | News | Comments

In the suit, Acura alleges that a generic of Acura's AVERSION® oxycodone product, previously marketed by Pfizer under its brand name OXECTA®, for which Sandoz is seeking approval to market in the United States pursuant to an Abbreviated New Drug Application filing with the FDA infringes a U.S. patent owned by Acura.

Another AstraZeneca Shareholder Voices Criticism

May 21, 2014 2:13 pm | News | Comments

Another AstraZeneca shareholder has criticized the pharmaceutical company's handling of Pfizer's $119 billion takeover bid, saying Wednesday it was "arguably wrong" to reject it so quickly.          

GlycoMimetics Receives $15M Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial

May 21, 2014 8:27 am | News | Comments

GlycoMimetics announced that Pfizer has made a $15M payment to the company under the terms of the parties’ collaboration for the development of rivipansel ( GMI-1070 ). Under the collaboration, Pfizer plans to initiate a Phase 3 clinical trial of rivipansel, which will trigger an additional $20M milestone payment.


AstraZeneca Shareholder Urges Pfizer Rethink

May 20, 2014 9:02 am | News | Comments

AstraZeneca shareholder Schroders has urged the pharmaceutical firm to reconsider its rejection of a takeover offer from U.S. drugmaker Pfizer. The fund manager, which holds a 2 percent stake in AstraZeneca, is the biggest shareholder to call publicly for renewed takeover talks.

AstraZeneca Board Rejects New Offer from Pfizer

May 19, 2014 7:59 am | by GREGORY KATZ, Associated Press; LINDA A. JOHNSON, Associated Press | News | Comments

The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that has caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

Pfizer Seeks Early Approval for Breast Cancer Drug

May 16, 2014 1:36 pm | by The Associated Press | News | Comments

The company says that after discussions with the FDA, the final results of a study called PALOMA-1 will be sufficient for review. The FDA last year designated palbociclib a breakthrough therapy, which speeds up the testing and approval process.

As Pfizer Fights it Out in Britain, US Lawmakers are Making Their Move in the Long Game

May 16, 2014 9:03 am | by Brian Williamson, Managing Director, Jumpstart | Blogs | Comments

While British attention in the Pfizer-AstraZeneca takeover battle has been focused on clashes between MPs and Pfizer chief executive Ian Read, events have been unfolding across the Atlantic which could have an infinitely greater bearing on where the pharma giant eventually conducts its business.

Pfizer's Troubles Across the Pond

May 15, 2014 8:51 am | Videos | Comments

Why are British protectionists trying to block a proposed pharmaceutical merger?                             

Pfizer Chief Says Jobs Will Go in Takeover

May 13, 2014 1:48 pm | by DANICA KIRKA, Associated Press | News | Comments

Pfizer Inc.'s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses — but promised to keep key research jobs in Britain as part of its $106 billion takeover bid.       

Lawmakers Press Pfizer CEO for Job Guarantees

May 13, 2014 7:58 am | by DANICA KIRKA, Associated Press | News | Comments

British lawmakers pressed the chief executive of Pfizer on Tuesday to guarantee jobs should the American company succeed in taking over London-based AstraZeneca, prodding him on whether he could be trusted to honor promises made as part of the bid.

Pfizer Argues for AstraZeneca Deal in Web Videos

May 12, 2014 8:31 am | by BERNARD CONDON, AP Business Writer | News | Comments

In four videos on Pfizer's website, CEO Ian Read sought to allay concerns that the deal would lead to a loss of stature in science in the United Kingdom. He said Pfizer had expanded its research in Cambridge, Massachusetts, and envisions pursuing a similar strategy for Britain's Cambridge, north of London, where many scientists work.

UK PM Says He's Playing Fair on AstraZeneca Deal

May 12, 2014 8:26 am | by DANICA KIRKA, Associated Press | News | Comments

With fears growing that British jobs will be lost and the nation's science base undermined in the potential merger, Prime Minister David Cameron denied in a BBC interview that he was favoring the American company.      

AstraZeneca Fends Off Pfizer with New Growth Plan

May 6, 2014 2:54 pm | by SYLVIA HUI, Associated Press | News | Comments

AstraZeneca has outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.        

Pfizer Mulls Options after AstraZeneca Snubs Offer

May 5, 2014 2:39 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Executives at drugmaker Pfizer Inc. say they're continuing to review options after British rival AstraZeneca PLC again rejected their proposal to buy the company, adding that Pfizer would prefer a friendly deal. The latest offer was valued at over $100 billion.

Pfizer First Quarter Profit Drops 15% Due to Lower Sales

May 5, 2014 8:34 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Pfizer said today that its first-quarter profit dropped 15 percent despite sharp cost cutting. The earnings decline reflected cheaper generic competition that continues to reduce sales of its multiple medicines and the end of some partnerships with other drugmakers.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.